Opiant Pharmaceuticals Investor Relations Material
Latest events
Q2 2022
Opiant Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Opiant Pharmaceuticals Inc
Access all reports
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company's lead product candidate is naloxone nasal spray that is in Phase III clinical trial for the treatment of opioid overdose. It also engages in developing temporary user-based treatment targeting at treating binge eating disorder (BED); as well as nasal treatments for other addictive/compulsive behaviors and disorders.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
OPNT
Country
🇺🇸 United States